

BMJ Open A long-term, observational cohort study on the safety of low-dose glucocorticoids in ankylosing spondylitis: adverse events and effects on bone mineral density, blood lipid and glucose levels and body mass index

Yu-Ping Zhang,¹ Yao Gong,^{1,2} Qing Yu Zeng,^{1,2} Zhi-Duo Hou,¹ Zheng-Yu Xiao¹

To cite: Zhang Y-P, Gong Y, Zeng QY, *et al.* A long-term, observational cohort study on the safety of low-dose glucocorticoids in ankylosing spondylitis: adverse events and effects on bone mineral density, blood lipid and glucose levels and body mass index. *BMJ Open* 2015;**5**:e006957. doi:10.1136/bmjopen-2014-006957

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2014-006957>).

Y-PZ and YG contributed equally.

Received 20 October 2014

Revised 7 May 2015

Accepted 8 May 2015



CrossMark

¹Department of Rheumatology, The First Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, China
²Research Unit of Rheumatology, Shantou University Medical College, Shantou, Guangdong, China

Correspondence to Zheng-Yu Xiao; deanyu@163.com

ABSTRACT

Objectives: This study aimed to investigate the risk of adverse events and effects on bone mineral density (BMD), blood lipid and glucose levels and body mass index (BMI) of low-dose glucocorticoid (GC) treatment in ankylosing spondylitis.

Design: We performed a retrospective, observational cohort study. Adverse effects were compared between GC users and non-GC users, and we analysed differences in the duration of GC exposure (no GC exposure, <6 months, 6 months to 2 years and >2 years).

Setting: Outpatient clinic in a tertiary general hospital in China, rheumatology follow-up visits over the past 30 years.

Participants: We included 830 patients with ankylosing spondylitis who were followed up for at least 6 months without a previous history or current complications of active gastrointestinal problems, hypertension, psychiatric or mental problems, diabetes mellitus, tuberculosis and hepatitis. The median follow-up time was 1.6 years (range 0.5–15 years, a total of 1801 patient-years).

Results: A total of 555 (66.9%) patients were treated with low-dose GCs, and the median cumulative duration of GC therapy was 1.3 years (range 0.1–8.5 years). Dermatological incidents, including acne, bruising and cutaneous infections, were the most common adverse events, with a cumulative incidence rate of 5.4% (22.2 events per 1000 patient-years), followed by a puffy and rounded face (1.6%), symptoms of weight gain (1.1%) and serious infections (1.0%). The rates of all other types of adverse events were less than 1%. The GC groups (GC users and non-GC users) and the duration of GC therapy were not associated with the frequency of low BMD, dyslipidaemia, hyperglycaemia or obesity ($p < 0.05$).

Conclusions: Adverse events during long-term treatment of low-dose GCs are limited. Low-dose GCs do not have an adverse effect on BMD, blood lipid and glucose levels and BMI.

Strengths and limitations of this study

- The strengths of our study include the large sample and long-term observation.
- To the best of our knowledge, the current study is the first to investigate the safety of low-dose glucocorticoids (GCs) in patients with ankylosing spondylitis (AS).
- In addition to reporting the absolute risk of adverse events, we directly compared the bone mineral density, blood lipid and glucose levels and body mass index in a large number of patients to evaluate the effects of low-dose GCs on patients with AS.
- Confounding factors were the main limitations of this retrospective observational design.

INTRODUCTION

Glucocorticoids (GCs) were introduced for the treatment of rheumatic disease in the 1950s, and their dramatic effects inspired physicians and patients. However, as the side effects and toxicity of long-term treatment with GCs (usually at doses that were median or high rather than low) emerged, physicians gradually lost confidence in GCs. Interestingly, in the last decade, GCs were reassessed in low-dose form. A large number of studies have shown that adverse events (AEs) of low-dose GCs in rheumatoid arthritis are moderate as long as the dose is low.^{1 2} However, in another chronic inflammatory disease, ankylosing spondylitis (AS), related research on GCs is scarce. Concerns about side effects may be one of the reasons why low-dose GCs are not commonly used in AS.³ Therefore, assessment of the safety of low-dose GC treatment in AS is important so that physicians can weigh the benefits against

the potential risks based on evidence when they prescribe this conventional antirheumatic drug.

In the late 1980s, low-dose GCs were used for treatment of several patients with AS who were refractory to non-steroidal anti-inflammatory drugs (NSAIDs) in our clinic, and the results were satisfactory. Therefore, since the 1990s, low-dose GCs have been used more widely in AS, depending on the disease activity of patients. In our clinic, low-dose GCs were used in a large number of patients with AS with a long period of follow-up. Therefore, we performed a retrospective, observational cohort study to determine the safety of low-dose GCs in patients with AS.

PATIENTS AND METHODS

Patients

Our rheumatology department was established in 1983, and is one of the earliest specialised departments for rheumatic disease in China. Over the past 30 years, more than 2000 patients with AS were treated and followed up in our clinic. This study included patients who fulfilled the modified New York criterion,⁴ and were followed up for at least 6 months in the Rheumatology Outpatient Department of the First Affiliated Hospital of Shantou University Medical College from 1983 to 2012. Owing to the known AEs of lengthy GC therapy, the following exclusion criteria were applied: a previous history or current complications of active gastrointestinal problems, hypertension, psychiatric or mental problems, diabetes mellitus, tuberculosis and hepatitis. Demographics and patients' characteristics, including age, sex, duration of disease, duration of follow-up (for GC users, this started from the time of initiating low-dose GCs), height, weight, human leucocyte antigen (HLA) B27, erythrocyte sedimentation rate (ESR), C reactive protein (CRP) levels at baseline, and data reflecting disease severity, such as the level of sacroiliac joint (SIJ) grading, and osteophytes in radiography of the spine were collected. Finally, 830 patients were included in this study. Among them, 188 patients were first-time visitors to our department during 1983–1999, and 642 patients during 2000–2012. At the time of analysis, follow-up data until June 2014 were available. The patients provided informed written consent for the use of their data. The data were anonymously analysed.

Treatment, patient follow-up and AEs monitoring

Low-dose GC users took 10 mg prednisone or 8 mg methylprednisolone tablets at 8:00, and a dose of NSAIDs (usually 90 mg acemetacin, 50 mg indomethacin or 7.5 mg meloxicam) before bedtime. Non-GC users only took a dose of NSAIDs before bedtime. Information regarding the dose of GC and duration of exposure was collected and categorised by cumulative duration of GC therapy as follows: no GC exposure (never took GCs), <6 months, 6 months to 2 years and >2 years. All patients were treated with conventional disease-modifying

antirheumatic drugs, single or combined, depending on the disease activity. Conventional disease modifying antirheumatic drugs (DMARDs) that are used by rheumatologists in our department include sulfasalazine, methotrexate, azathioprine, thalidomide and some extracts of Chinese herbs, including *Tripterygium wilfordii* Hook F and total glucosides of paeony. All the patients took oral calcium and vitamin D concurrently, unless there was a specific contraindication.

In our clinic, all the patients were followed up every 1–3 months once the diagnosis was made and treatment strategies were decided. Physicians inquired about medication compliance and AEs, assessed disease activity at every visit, and all AEs were required to be recorded in the medical records. Routine blood examination, liver and renal functions and ESR and CRP levels were required to be tested at intervals of 1 month to half a year. BMD, blood lipid and glucose levels and BMI were required to be measured at intervals of 1 year. The DXA (dual energy X-ray absorptiometry) scanner was introduced to our hospital in 2005; BMD was not tested prior to that year. There were five to six doctors who regularly worked at our outpatient department. They followed the routines for each patient's follow-up, and the decision whether to do a test or not were based on opinions of rheumatologists and the willingness of the patients.

Assessment of AEs

Definition: An adverse drug reaction was defined according to WHO definition, which refers to any noxious, unintended and undesired effect of a drug, which occurs at doses used in humans for prophylaxis, diagnosis or therapy.⁵

By systematically reviewing clinical records, we investigated eight categories of AEs, which may be related to GCs, and were recommended to be monitored under low-dose GC treatment by the European League Against Rheumatism (EULAR).⁶ (1) cardiovascular system: hypertension, ischaemic cardiovascular disease; (2) serious infections: only infections that required hospitalisation or were life-threatening were counted because mild infections such as uncomplicated lower urinary tract and upper airway infections may be missed by the patients or may not be accurately assessed and/or recorded by the rheumatologist during the visit; (3) gastrointestinal system: peptic ulcer disease (confirmed by gastroscopie examination); (4) mood disturbances, sleep disorder; (5) endocrine and metabolic system: diabetes, body weight gain and fat redistribution; (6) dermatological system: acne, hirsutism, alopecia, bruising and cutaneous infection; (7) musculoskeletal system: fragility fracture and (8) ophthalmological system: cataract. All the comorbidities were confirmed by the physician.

Furthermore, to assess the effects of low-dose GC treatment on bone mineral density (BMD), blood lipid and glucose levels and body mass index (BMI), we analysed related data and compared them between the two groups. By reviewing clinical data, we collected original

BMD data of 317 patients, fasting glucose levels of 335 patients, blood lipid levels of 190 patients and the BMI of 367 patients after treatment (the latest results for those who underwent more than one test were analysed). BMD was measured using a DXA scanner (DXA, DMS Lessos, France) in our hospital at the lumbar spine, the hip and the non-dominant forearm. For patients under the age of 50, 'below the expected range for age' was defined as a Z-score <-2.0 at more than one of the aforementioned sites. For patients aged 50 years or older, the WHO definitions of osteopenia and osteoporosis were used: osteopenia, $-2.5 < \text{T-score} < -1 \text{ SD}$, and osteoporosis, $\text{T-score} < -2.5 \text{ SD}$.⁷ Considering that only 14 patients who had their BMD tested were older than 50 years, 'BMD below the expected range for age' and 'osteoporosis' are expressed conformably as 'low BMD' in this article. BMI is calculated as (weight in kilograms)/(height in metres²). According to 'the guidelines for prevention and control of overweight and obesity in Chinese adults', obesity is defined as a BMI over 28 kg/m², while overweight is defined as a BMI between 24.0 and 27.9 kg/m².⁸ For teenagers under the age of 18, criteria with respect to their age are used.⁹ Dyslipidaemia is defined as the value exceeding these normal ranges (mmol/L): cholesterol (CHOL) 3.10–6.00; triglycerides (TRIG) 0.45–1.6; high-density lipoprotein (HDL) 0.8–2.35; low-density lipoprotein (LDL) 1.68–4.5. Hyperglycaemia is defined as a fasting blood glucose of at least 6.1 mmol/L. All blood tests were analysed by a single laboratory in our hospital.

Statistical analysis

All the data were analysed using SPSS software V.20.0 for Windows. Continuous data are presented as mean \pm SD, and categorical data are presented as numbers (n) or proportions (%). Baseline differences in patients' characteristics between groups were analysed by the χ^2 test for categorical data or the Mann-Whitney U test for continuous data. The cumulative incidence rate and rate per 1000 patient-years of follow-up (duration of follow-up (years) \times number of patients) were reported for GC-related AEs. For incidents that may occur repeatedly, such as cutaneous infection, only the first incident was included in the analysis of cumulative incidence, and only the first incident that occurred in 1 year was included in the analysis of the rate per 1000 patient-years of follow-up. The effects of low-dose GCs on BMD, blood lipid and glucose levels and BMI were modelled using multiple logistic regression analysis, controlling for potential confounding factors when appropriate. p Values less than 0.05 were considered statistically significant.

RESULTS

Characteristics in different subgroups

The study comprised 830 patients with a mean age of 28 \pm 10 years (range 10–62 years). The mean duration of disease was 6.5 \pm 6.0 years (range 0.25–40 years), and the

HLA-B27-positive rate was 88.5%. The mean follow-up duration was 2.2 \pm 1.9 years (median 1.6 years; range 0.5–15 years). The overall follow-up was 1801 patient-years. Among them, 217 (26.1%) patients were followed up for more than 3 years.

Characteristics in different subgroups are shown in table 1. A total of 555 (66.9%) patients were treated with low-dose GCs, and the median cumulative duration of GC therapy was 1.3 years (range 0.1–8.5 years). Among them, 319 (57.5%) patients took low-dose GCs for more than 1 year, and 98 (17.7%) patients took them for more than 3 years. The median cumulative dose of GCs was 3.7 g (range 0.13–29 g). The other 275 patients were non-GC users, and they showed no differences from GC users regarding age, sex, disease duration or HLA-B27-positive rate. However, more patients in the GC group reached the SIJ-IV grading level at baseline, and the ESR and CRP levels at baseline were higher compared with the non-GC group. The mean duration of follow-up in the GC group was 2.4 \pm 2.1 years, which was significantly longer than that in the non-GC group (1.6 \pm 1.3 years, $p=0.000$). The overall follow-up of GC users was longer than that of non-GC users (1349 vs 452 patient-years).

AEs under low-dose GC treatment

The number of GC-related AEs was limited (table 2). Dermatological incidents, including acne, bruising and cutaneous infections, were the most common AEs, with a cumulative incidence rate of 5.4% (22.2 events per 1000 patient-years), followed by a puffy and rounded face, complaint of obvious weight gain and serious infections. The cumulative incidence rates of all the other

Table 1 Characteristics of the different subgroups

	GC group	Non-GC group	p Value
Number of cases	555	275	
Age, mean \pm SD, years	28 \pm 9	28 \pm 10	0.420
Disease duration, mean \pm SD, years	6.7 \pm 5.9	6.2 \pm 6.1	0.085
HLA-B27 positive, n (%) [*]	393 (88.5)	152 (88.4)	0.961
Male sex, n (%)	242 (88)	480 (86.5)	0.542
SIJ grade IV, n (%)	58 (21.1)	165 (29.7)	0.008
Spinal osteophytes, n (%) [*]	79 (30.6)	179 (34.4)	0.289
ESR at baseline, mm/1 h [*]	40 \pm 28	30 \pm 25	0.000
CRP at baseline, mg/L [*]	25.8 \pm 26.5	20.5 \pm 26.7	0.002
Duration of follow-up, mean \pm SD, years	2.4 \pm 2.1	1.6 \pm 1.3	0.000
Duration of GC therapy, mean \pm SD, years	1.7 \pm 1.6		

^{*}Some data were missing in these items at baseline: 214 cases of HLA-B27, 52 cases of spinal osteophytes, 80 cases of ESR, 178 cases of CRP.

CRP, C reactive protein; ESR, erythrocyte sedimentation rate; GC, glucocorticoid; HLA, human leucocyte antigen; SIJ, sacroiliac joint.

Table 2 GC-related AEs under low-dose GC treatment compared with non-GC users

Adverse events	GC group (n=555)	AE/1000 PY N=1349	Duration of GC therapy by the time of AEs (median, days)	Non-GC group (n=275)	AE/1000 PY N=452
Hypertension	4 (0.7)	3.0	43	1 (0.4)	2.2
Serious infections	6 (1.0)	4.4	230	2 (0.7)	4.4
Peptic ulcer disease	4 (0.9)	3.0	691	4 (1.5)	8.8
Sleep disorder, mood disturbances	3 (0.5)	2.2	264	1 (0.4)	2.2
Diabetes	1 (0.2)	0.7	96	0	0
Symptom of weight gain	6 (1.1)	4.4	132	0	0
Puffy and rounded face	9 (1.6)	6.7	60	0	0
Dermatological AEs	30 (5.4)*	22.2		3 (1.0)*	6.6
Acne, bruising	17 (3.1)	12.6	180	0	0
Cutaneous infection	13 (2.3)	9.6	365	3 (1.0)	6.6
Fragility fracture	0	0		1 (0.3)	2.2

*p=0.003.

The incidence rates of AEs in the table are expressed as cumulative rate n (%) or events per 1000 PY. AEs, adverse events; GC, glucocorticoid; PY, patient-years.

types of AEs were less than 1%. The median cumulative duration of GC therapy by the time of AEs was less than 1 year, except for peptic ulcer disease. The mean age of patients with hypertension was 45±6 years, which is much higher than the average value of the population, with a median cumulative duration of GC therapy of 43 days (range 13–90 days). One patient in the GC group was diagnosed with diabetes at the age of 35 years, with a cumulative duration of GC therapy of 210 days. No cardiovascular events were reported in any of the patients who were followed up. In the non-GC group, no complications of diabetes, symptoms of weight gain, a puffy and rounded face, acne or bruising were reported. The non-GC group showed a comparable incidence rate for the other types of AEs, except for dermatological AEs, which was significantly lower than that of the GC group (p=0.003; table 2).

Effect of low-dose GCs on BMD, blood lipid and glucose levels and BMI

Univariate analysis

The BMD of 49 (23.8%) patients in the GC group was low after a mean duration of GC therapy of 2.2±1.8 years (median 1.6 years). This finding was comparable with 23 (20.7%) patients with a low BMD in the non-GC group after treatment, with a relative risk of 1.15 (95% CI 0.74 to 1.7). There were no significant differences in the proportion of patients with dyslipidaemia, hyperglycaemia and obesity between the GC and non-GC groups (table 3). Moreover, patients with a cumulative duration of low-dose GCs for longer than 2 years showed a similar prevalence of low BMD, dyslipidaemia, hyperglycaemia and obesity to that of non-GC users. As the cumulative time of GCs increased, the proportion of patients with abnormal cholesterol, triglycerides and low-density lipoprotein tended to decrease (table 3).

Multivariate analysis

The associations between GC exposure and the frequency of low BMD, overweight, obesity, hyperglycaemia and dyslipidaemia were assessed using a logistic regression model. Confounding factors (independent variables) for low BMD included age, male sex, BMI, ESR at baseline, GC groups (GC users or non-GC users), cumulative duration of GC therapy and spinal osteophytes. Confounding factors for overweight and obesity included age, GC groups and cumulative duration of GC therapy. Confounding factors for hyperglycaemia, and dyslipidaemia included age, BMI, ESR at baseline, GC groups and cumulative duration of GC therapy.

In multivariate analysis, GC groups and the duration of GC therapy were not associated with the frequency of low BMD, overweight, obesity, hyperglycaemia or dyslipidaemia. Low BMD was associated with male sex (OR 7.546, 95% CI 1.626 to 35.011), BMI (OR 0.695, 95% CI 0.606 to 0.797) and spinal osteophytes (OR 2.520, 95% CI 1.115 to 5.697). Overweight was associated with age (OR 1.064, 95% CI 1.038 to 1.091).

DISCUSSION

We conducted this study to investigate the safety of low-dose GCs in patients with AS. To the best of our knowledge, this study is the first to examine AEs of low-dose GCs in patients with AS. Our large sample, long-term observational study showed that the number of GC-related AEs was limited. Dermatological incidents were the most common AEs. GC users did not have a higher prevalence of hypertension, serious infections, peptic ulcer disease, sleep disorders or mood disturbances than non-GC users. This finding is consistent with the conclusion of some meta-analyses on rheumatoid arthritis that AEs of low-dose GC users were often not significantly different from those with placebo.^{1 2} However,

Table 3 Comparison of the proportion of patients with low BMD, abnormal blood lipid and blood glucose levels, overweight and obesity between GC users and non-GC users

	RR value (GC users vs non-GC users)	Non-GC users	GC users	Grouping by duration of GC therapy		
				GCs<0.5 years	GCs 0.5–2 years	GCs >2 years
BMD						
Number of cases		111	206	26	89	91
Low BMD, n (%)	1.15 (0.74–1.78)	23 (20.7)	49 (23.8)	4 (15.4)	24 (27.0)	21 (23.1)
Blood lipids						
Number of cases		61	129	22	68	39
Elevated CHOL, n (%)	2.84 (0.66–12.35)	2 (3.3)	12 (9.3)	2 (9.1)	9 (13.2)	1 (2.6)
Elevated TG, n (%)	0.68 (0.31–1.51)	9 (14.8)	13 (10.1)	2 (9.1)	8 (11.8)	3 (7.7)
Decreased HDL,* n (%)	0.64 (0.11–3.75)	2 (3.6)	3 (2.3)	0	2 (3.0)	1 (2.6)
Elevated LDL,* n (%)	2.18 (0.26–18.18)	1 (2.5)	4 (4.1)	1 (4.5)	3 (4.6)	1 (2.6)
Blood glucose						
Number of cases		136	199	54	92	52
Elevated glucose, n (%)	0.273 (0.05–1.39)	5 (3.7)	2 (1.0)	0	2 (2.2)	0
BMI						
Number of cases		137	230	31	119	80
Overweight, n (%)	0.74 (0.49–1.11)	33 (24.1)	41 (17.8)	5 (16.1)	20 (16.8)	16 (20.0)
Obesity, n (%)	1.64 (0.53–5.05)	4 (2.9)	11 (4.8)	0	8 (6.7)	3 (3.8)

All the p values between the GC subgroup (GCs <0.5, 0.5–2 or >2 years) and non-GC users were over 0.05.

*Out of the patients who had their blood lipids tested after treatment, six cases missed the data of HDL, and eight cases missed the data of LDL.

BMD, bone mineral density; BMI, body mass index; CHOL, cholesterol; GC, glucocorticoid; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RR, relative risk; TG, triglyceride.

in some observational studies on older patients, such as those with rheumatoid arthritis and polymyalgia rheumatica, the incidence rate of GC-related AEs was usually much higher than that in our study, and it was associated with duration of GC exposure, especially osteoporosis, fragility fractures and hypertension.^{10–12} A relatively young age may be one of the reasons why comorbidity of hypertension, diabetes and cardiovascular events are scarce. A young population usually has less concurrent disorders, such as diabetes and hypertension, than an old population, and a longer duration of follow-up might be needed. However, similar levels of blood glucose and lipids and BMI between GC users and non-GC users in our study suggest that low-dose GCs do not have an adverse effect on the aforementioned events in the long term in patients with AS.

Another unique feature of this study is that we directly compared BMD, blood lipid and glucose levels and BMI in a large number of patients to evaluate the effect of low-dose GC on AS. Bone loss is assumed to be a common AE of GCs.¹³ In our study, in the GC group, even the number of long-term users with low BMD was similar to that in the non-GC group. Patients with AS have a high prevalence of low BMD due to the inflammatory nature of the disease.^{14 15} This study showed that low-dose GCs did not have an adverse effect on BMD in AS. Similarly, some studies on the BMD of patients with rheumatoid arthritis also indicated that low-dose GC treatment does not lead to bone loss, and may even improve BMD by controlling the disease activity.^{16 17} In this study, GC exposure was not associated with the

frequency of hyperglycaemia, dyslipidaemia and obesity. Patients with AS have a higher risk of metabolic syndrome and cardiovascular events due to an elevated inflammation level.^{18 19} Our finding of decreased abnormal levels of cholesterol, triglycerides and low-density lipoprotein as the cumulative time of GCs increased may be related to control of inflammation. Similarly, some studies did not show any association between GC use and abnormal blood lipid levels or the presence of metabolic syndrome in rheumatic disease.^{20 21} In general, GCs have a complicated effect on blood lipid and glucose levels and BMD in inflammatory rheumatic disease. Control of inflammation by GCs improves the abnormal metabolism of blood lipid and glucose levels and an abnormal course of bone remodelling. However, GCs can also aggravate these outcomes. Low-dose GCs may be a good balance point between these two opposite outcomes.

Low-dose GCs were not recommended in AS in the Assessment of SpondyloArthritis International Society (ASAS)/EULAR management recommendation due to lack of evidence.²² However, to the best of our knowledge, traditional antirheumatic drugs, including low-dose GCs, still play a role in the treatment of AS and need to be reassessed in more studies, especially on patients at the early stage of disease. We were not in a minority in using low-dose GCs in the treatment of AS in China regarding its cost-effectiveness. Even in the European countries, related articles reported that from baseline data of early studies with antitumour necrosis factor agents and other agents, 10–25% of patients with AS are treated more or less continuously with GCs, and the German collaborative arthritis

centre's database registered a current treatment with low-dose GC therapy in 15.6% of the patients with AS.²³ Actually, there is no reasonable doubt that GCs could improve the symptoms of AS, considering its greater anti-inflammatory properties than NSAIDs. However, there were no clinical studies evaluating the effectiveness of low-dose corticosteroids in AS. The comment following the ASAS/EULAR management recommendation about GCs was "there have been no new studies, and the available literature is still scarce."²² Our study may be the first attempt to reassess the value of low-dose GCs to patients with AS, as concerns about side effects may be one of the reasons why low-dose GCs are not commonly used in AS.³ Our study could help physicians to weigh the benefits against the potential risks when they prescribe this conventional antirheumatic drug in clinical practice.

As a retrospective cohort study, there were inevitably some limitations. First, confounding factors were the main limitation for this observational design. We have adjusted for potential confounding factors by a regression model, but the adjustment itself had limitations due to the retrospective nature of this study. Second, as not all the patients had their BMD, BMI or blood glucose tested after treatment, the missing data may be a bias. However, as an original clinical database with consecutive patients, some data may be kind of randomly missed. Third, adverse events of GCs, like cardiovascular events and diabetes, were usually chronic incidents during long-term treatment, and therefore the median follow-up duration of 1.6 years may not be sufficiently long enough to evaluate the long-term safety. We are looking forward to more well-designed studies to confirm our results.

In conclusion, our study shows that AEs during long-term treatment of low-dose GCs are limited. Low-dose GCs do not have an adverse effect on BMD, blood lipid and glucose levels, or BMI. In the young and mainly male population of patients with AS, low-dose GCs are relatively safe. Our findings may help physicians and rheumatologists to gain new insight into the traditional antirheumatic drugs that are GCs.

Acknowledgements Language editing services were provided by Edanz.

Contributors Y-PZ, YG and Z-YX contributed to the conception and design of the work. Y-PZ, YG, Z-DH, QYZ and Z-YX contributed to the acquisition, analysis and interpretation of the data. Y-PZ and YG drafted the work and all authors revised it critically for important intellectual content. All authors gave final approval of the version to be published.

Competing interests None declared.

Ethics approval The institutional ethics committee of Shantou University Medical College.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

1. Hoes JN, Jacobs JWG, Verstappen SMM, *et al.* Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. *Ann Rheum Dis* 2009;68:1833–8.
2. Da Silva JA, Jacobs JW, Kirwan JR, *et al.* Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. *Ann Rheum Dis* 2006;65:285–93.
3. Van der Goes MC, Jacobs JW, Boers M, *et al.* Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. *Ann Rheum Dis* 2010;69:1015–21.
4. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum* 1984;27:361–8.
5. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *Lancet* 2000;356:1255–9.
6. van der Goes MC, Jacobs JWG, Boers M, *et al.* Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. *Ann Rheum Dis* 2010;69:1913–19.
7. Schousboe JT, Shepherd JA, Bilezikian JP, *et al.* Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on Bone Densitometry. *J Clin Densitom* 2013;16:455–67.
8. Disease Control Division of Ministry of Health of The people's Republic of China. The guidelines for prevention and control of overweight and obesity in Chinese adults. Beijing: People's Medical Publishing House 2006:3–4. Chinese.
9. Group of China Obesity Task Force. [Body mass index reference norm for screening overweight and obesity in Chinese children and adolescents]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2004;25:97–102.
10. Malysheva OA, Wahle M, Wagner U, *et al.* Low-dose prednisolone in rheumatoid arthritis adverse effects of various disease modifying antirheumatic drugs. *J Rheumatol* 2008;35:979–85.
11. Mazzantini M, Torre C, Miccoli M, *et al.* Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. *J Rheumatol* 2012;39:552–7.
12. Mazzantini M, Talarico R, Doveri M, *et al.* Incident comorbidity among patients with rheumatoid arthritis treated or not with low-dose glucocorticoids: a retrospective study. *J Rheumatol* 2010;37:2232–6.
13. Canalis E, Mazziotti G, Giustina A, *et al.* Glucocorticoid-induced osteoporosis: pathophysiology and therapy. *Osteoporos Int* 2007;18:1319–28.
14. van der Weijden MA, Claushuis TA, Nazari T, *et al.* High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. *Clin Rheumatol* 2012;31:1529–35.
15. Klingberg E, Lorentzon M, Mellstrom D, *et al.* Osteoporosis in ankylosing spondylitis—prevalence, risk factors and methods of assessment. *Arthritis Res Ther* 2012;14:R108.
16. Engvall IL, Brismar K, Hafstrom I, *et al.* Treatment with low-dose prednisolone is associated with altered body composition but no difference in bone mineral density in rheumatoid arthritis patients: a controlled cross-sectional study. *Scand J Rheumatol* 2011;40:161–8.
17. van der Goes MC, Jacobs JW, Jurgens MS, *et al.* Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? *Osteoporos Int* 2013;24:1429–36.
18. Papadakis JA, Sidiropoulos PI, Karvounaris SA, *et al.* High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. *Clin Exp Rheumatol* 2009;27:292–8.
19. Heeneman S, Daemen MJ. Cardiovascular risks in spondyloarthritis. *Curr Opin Rheumatol* 2007;19:358–62.
20. Boers M, Nurmohamed MT, Doelman CJA. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. *Ann Rheum Dis* 2003;62:842–5.
21. Toms TE, Panoulas VF, Douglas KM, *et al.* Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. *Arthritis Res Ther* 2008;10:R145.
22. Braun J, van den Berg R, Baraliakos X, *et al.* 2010 Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis* 2011;70:896–904.
23. Spies CM, Burmester GR, Buttgerit F. Analyses of similarities and differences in glucocorticoid therapy between RA and AS. *Clin Exp Rheumatol* 2009;27(Suppl 55):S152–8.